-+ 0.00%
-+ 0.00%
-+ 0.00%

Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate

Benzinga·08/10/2026 11:22:01
Listen to the news
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 84.21 percent increase over losses of $(0.57) per share from the same period last year.